CMS proposes faster prior authorization for some drug requests
CMS has proposed new prior-authorization and interoperability rules that could speed up drug coverage decisions for some plans if finalized. The main promise is less waiting and more transparency — but the change is still only a proposal, and details can still change after public comment.
The main takeaway: CMS has proposed a new rule that could make prior authorization faster and more transparent for some drug requests. If finalized, it would extend electronic prior authorization requirements to certain drugs and set tighter decision timelines for several public coverage programs.
For patients and families, that could mean fewer delays when a medicine needs insurance approval. But the rule is still a proposal, so the exact requirements, timelines, and scope could change after public comment and before any final rule takes effect.
What CMS is proposing
CMS says the proposal would build on earlier interoperability and prior authorization rules and bring drugs into a more standardized electronic workflow. The agency says the goal is to improve transparency, reduce paperwork, and speed up decisions.
Under the proposal, impacted payers would have to support electronic prior authorization for drugs covered under medical benefit plans beginning October 1, 2027. CMS is also proposing electronic prior authorization support for certain pharmacy benefit drug requests in state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federal Marketplace.
Who could be affected
The proposal would affect Medicare Advantage plans, Medicaid and CHIP programs, and Marketplace plans on the federally facilitated exchanges. CMS says the changes are meant to make the process more consistent for providers and patients across programs.
That said, coverage rules still vary by plan, state, and benefit type. A drug that needs prior authorization in one plan may not in another, and the way a request is handled can still depend on the insurer and the care setting.
What could change for patients
CMS says the proposal would require faster notice of prior authorization decisions for certain drug requests. For Medicaid and CHIP fee-for-service programs and managed care plans, CMS proposes a 24-hour decision window for drugs. For Marketplace plans, the proposal would require decisions within 72 hours for standard requests and 24 hours for expedited requests.
The agency is also proposing that denials for drug prior authorization requests include a specific reason. For patients, that could make it easier to understand what went wrong and what information may be needed for an appeal or resubmission.
CMS also proposes public reporting of drug prior authorization metrics, which could give patients, clinicians, and researchers a clearer view of how often requests are approved, denied, appealed, and delayed.
What is already in place
This proposal builds on a 2024 final rule that already requires certain payers to support electronic prior authorization for non-drug items and services. CMS has said the earlier rule does not apply to drug prior authorization decisions, which is why this new proposal matters.
In plain terms: the system for some medical services is already moving toward more electronic, standardized prior authorization. This proposal would extend that approach to drugs as well.
What remains uncertain
The biggest unknown is whether CMS will finalize the proposal as written. Public comments can lead to revisions, and the final rule could differ in timing, scope, or reporting requirements.
It is also not yet clear how much the proposal would reduce delays in real-world practice. Prior authorization can still involve clinical review, and electronic systems do not automatically remove every barrier.
What readers can do
If you are waiting on a drug approval now, keep checking with your pharmacy and health plan for status updates. Ask whether the request is standard or expedited, whether any records are missing, and whether the plan can provide the reason for a denial in writing.
If a medication delay could affect your health quickly, contact the prescribing clinician’s office promptly. For urgent symptoms or signs of a medical emergency, seek immediate care.
For people who want to weigh in on the proposal, CMS says the public comment deadline is June 15, 2026.
Bottom line
This proposal would not eliminate prior authorization, but it could make the process faster and more transparent for some drug requests if finalized. For now, it is a proposed change, not a finished rule.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
